More grist for PCSK9 fight as Amgen sets up EU to pay about half as much as U.S.

Tracy Staton

Last week, won its -anticipated FDA approval for the cholesterol-fighter Repatha and promptly set a price of $ 14,100 per year. But even after pharmacy benefits managers and insurers wring out their discounts, the cost is unlikely to be nearly as low as Repatha's price tag in Europe.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS